ABX advanced biochemical compounds GmbH

Primo and ABX Partner to Introduce Advanced PSMA-Targeting Radiotracer for Prostate Cancer Diagnosis in Taiwan

2 months ago

• Primo Biotechnology has formed a strategic partnership with Germany's ABX to introduce PB01, an advanced diagnostic radiotracer for prostate cancer, to the Taiwanese market amid rising disease incidence and mortality rates. • PB01, equivalent to Europe's approved Radelumin, utilizes PET/CT imaging technology to precisely detect Prostate Specific Membrane Antigen (PSMA) expression, enabling more accurate identification and monitoring of prostate cancer. • The collaboration aims to address Taiwan's urgent need for improved diagnostic tools, with Radelumin having already established itself as a valuable asset for early detection, staging, and recurrence monitoring in high-risk prostate cancer cases across Europe since 2021.